Study of Dose-Dense Adriamycin Plus Cytoxan (AC) Followed by Either Abraxane or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

This study is ongoing, but not recruiting participants.

Study NCT00394251 Information provided by Abraxis BioScience Inc.

First Received: October 30, 2006 Last Updated: March 24, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	May 2008
Estimated Primary Completion Date:	May 2008 (Final data collection date for primary outcome measure)